CDT Equity Finalizes $1.46M Convertible Loan with J.J. Astor & Co. Amidst Financial Distress

summarizeSummary

CDT Equity Inc. secured the second tranche of a highly dilutive $1.46 million convertible loan, crucial for its survival but at significant cost to existing shareholders, amidst ongoing financial and compliance challenges.

check_boxKey Events · Financing and Capital Events · CDT

• Second Tranche of Convertible Loan Funded

  CDT Equity Inc. received the second tranche of $1,133,300.30 in net proceeds from a $1.46 million senior secured convertible loan from J.J. Astor & Co. on June 30, 2026. The total principal amount of the convertible note is $1,971,000, reflecting a 1.35x factor rate on the loan amount.

• Highly Dilutive Terms

  The convertible note includes conversion price discounts (90% of 10-day VWAP or 70% on default) and the issuance of 912,500 warrants with an exercise price of $0.72 per share. Weekly installment payments of $82,125 will commence on July 10, 2026, with the lender having the option to receive payments in cash or immediately salable Conversion Shares.

• ATM Proceeds Directed to Lender

  An ATM Waterfall Distribution agreement directs 80% of ATM financing net proceeds to the lender until weekly payments are met, then 50% until the note is paid in full. In case of default, 80% of ATM proceeds will go to the lender until the note is fully repaid.

• Strict Covenants and Compliance Deadlines

  The loan agreement includes covenants requiring the company to maintain 400% of the outstanding principal in registered, freely tradeable shares for ATM financing, timely file all SEC reports (including the overdue Q1 2026 10-Q by July 15, 2026), and take action for a reverse stock split if the share price falls below $1.00 to maintain Nasdaq listing.

auto_awesomeAnalysis · CDT · Life Sciences

CDT Equity Inc. has finalized the terms and received the second tranche of a $1.46 million senior secured convertible loan from J.J. Astor & Co., initially announced on June 16, 2026. This financing is critical for the company, which previously disclosed substantial doubt about its ability to continue as a going concern and received a Nasdaq deficiency letter for failing to file its Q1 2026 10-Q. The loan, structured as a $1,971,000 principal convertible note with a 1.35x factor rate, is highly dilutive, featuring conversion price discounts (90% of 10-day VWAP or 70% on default) and warrants for 912,500 shares. Strict covenants include maintaining 400% of the outstanding principal in ATM capacity, timely SEC filings (with a July 15, 2026 deadline for the overdue Q1 10-Q), and a mandatory reverse stock split if the share price falls below $1.00. While providing a necessary lifeline, the terms are very costly and reflect the company's precarious financial position.